News Releases

CEO Milan Patel talks the importance of detecting microbes for the National Cannabis Industry Association.

PathogenDX microarray bests testing technologies worldwide to win global innovation award.

New study shows end-point PCR technologies to be more accurate than Petri dish and real-time qPCR.

PathogenDx highlighted in Cannabis&Tech Today for testing multiple microbes in parallel.

PathogenDx partners with Icon Farms to elevate safety standards for testing hemp.

PathogenDx secures $7.5 million in Series B funding.

PathogenDx and Nationwide Laboratory Services Announce a Strategic Partnership to Deploy Ultra-Rapid Molecular Pathology for Rapid Strain Identification  

Global Market Expands for PathogenDX’s Preventative Environmental Monitoring Product for Microbials – Envirox™

PathogenDx Launches New Brand and Microbial Testing Products For Expanding Market

Growing Arizona Company PathogenDx Expands Staff and Footprint

PathogenDx Launches the World’s First Quantitative Microarray Test for Cannabis

PathogenDx Team Showcases Environmental Screening Products and DNA-Based Testing Technology at NCIA’s 5th Annual Cannabis Business Summit & Expo July 25-27 in San Jose – Booth #1519

DNA-Based Pathogen Testing Company PathogenDx Raises $3.4 Million in Convertible Note Round

News Coverage

PathogenDx, Inc., the Arizona based technology company which provides a DNA-based pathogen testing platform for the cannabis, hemp, agriculture and food safety industries announced today that they have entered into a strategic partnership with Nationwide Laboratory Services/The Hayes Division, a national medical lab testing company based in Florida, to deploy PathogenDx’s proprietary microarray technology for rapid strain identification in the dermatological and podiatric fungal testing industry.

 E. coli and Salmonella – these names strike fear in the heart of any food producer around the world. These microbes should strike even more fear for those who use medicinal cannabis for their health. The Food and Drug Administration (FDA) or United States Department of Agriculture are not monitoring cannabis, therefore there is no federal regulatory structure for cannabis currently in place.

E. coli and Salmonella – these names strike fear in the heart of any food producer around the world. These microbes should strike even more fear for those who use medicinal cannabis for their health. The Food and Drug Administration (FDA) or United States Department of Agriculture are not monitoring cannabis, therefore there is no federal regulatory structure for cannabis currently in place.

The technology, which has been developed by PathogenDx, has a host of other benefits, too. Assay samples don’t need to be enriched or incubated before testing and the technology can identify multiple microorganisms simultaneously. 

A PathogenDX sample holder can be used to detect 40 bacterial contaminants in each of 12 samples with a 6-hour test process. The company showed a new version of its technology at the New West Summit marijuana show.

Brandon David of Investing in Cannabis talked with Jon Trauben of Altitude Investments, a venture-capital fund based in New York that invests in early-stage and growth companies in the global cannabis industry.

Ever since Colorado legalized cannabis for all adults in 2014, the cannabis industry has blossomed, with a multitude of companies competing to scale up as more states legalize the drug.

Cannabis-focused investor Salveo Capital has taken a minority stake in PathogenDx Corp., a provider of testing technology for the cannabis and other agricultural industries.

Watch as photographer James Banasiak captures the many sides of Reggie Gaudino, PhD, Chief Science Officer for Steep Hill, for mg‘s June cover story titled “The Patent Whisperer.”Story by Tom Hymes, art direction by Angela Derasmo.